Blueprint Medicines Corp Stock Price Prediction
| BPMC Stock | USD 92.29 1.68 1.85% |
Oversold Vs Overbought
53
Oversold | Overbought |
Blueprint Medicines Corp stock price prediction is an act of determining the future value of Blueprint Medicines shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Blueprint Medicines' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Blueprint Medicines and does not consider all of the tangible or intangible factors available from Blueprint Medicines' fundamental data. We analyze noise-free headlines and recent hype associated with Blueprint Medicines Corp, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Blueprint Medicines' stock price prediction:EPS Estimate Next Quarter (1.75) | EPS Estimate Current Year (5.55) | EPS Estimate Next Year (2.78) | Wall Street Target Price 97.38 | EPS Estimate Current Quarter (2.04) |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Blueprint Medicines based on different types of headlines from major news networks to social media. The Blueprint stock price prediction module provides an analysis of price elasticity to changes in media outlook on Blueprint Medicines over a specific investment horizon. Using Blueprint Medicines hype-based prediction, you can estimate the value of Blueprint Medicines Corp from the perspective of Blueprint Medicines response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Blueprint Medicines using Blueprint Medicines' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Blueprint using crowd psychology based on the activity and movement of Blueprint Medicines' stock price.
Blueprint Medicines Short Interest
A significant increase or decrease in Blueprint Medicines' short interest from the previous month could be a good indicator of investor sentiment towards Blueprint. Short interest can provide insight into the potential direction of Blueprint Medicines stock and how bullish or bearish investors feel about the market overall. An investor who is long Blueprint Medicines may also wish to track short interest. As short interest increases, investors should be becoming more worried about Blueprint Medicines and may potentially protect profits, hedge Blueprint Medicines with its derivative instruments, or be ready for some potential downside.
200 Day MA 69.6922 | Short Percent 0.096 | Short Ratio 5.37 | Shares Short Prior Month 5.2 M | 50 Day MA 89.3588 |
Blueprint Medicines Corp Hype to Price Pattern
Investor biases related to Blueprint Medicines' public news can be used to forecast risks associated with an investment in Blueprint. The trend in average sentiment can be used to explain how an investor holding Blueprint can time the market purely based on public headlines and social activities around Blueprint Medicines Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Blueprint Medicines' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Blueprint Medicines.
Blueprint Medicines Implied Volatility | 68.02 |
Blueprint Medicines' implied volatility exposes the market's sentiment of Blueprint Medicines Corp stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Blueprint Medicines' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Blueprint Medicines stock will not fluctuate a lot when Blueprint Medicines' options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in Blueprint Medicines. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Blueprint Medicines to buy its stock at a price that has no basis in reality. In that case, they are not buying Blueprint because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Blueprint Medicines after-hype prediction price | USD 93.09 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Blueprint contract
Based on the Rule 16, the options market is currently suggesting that Blueprint Medicines Corp will have an average daily up or down price movement of about 4.25% per day over the life of the 2024-05-17 option contract. With Blueprint Medicines trading at USD 92.29, that is roughly USD 3.92 . If you think that the market is fully incorporating Blueprint Medicines' daily price movement you should consider acquiring Blueprint Medicines Corp options at the current volatility level of 68.02%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Blueprint |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Blueprint Medicines' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Blueprint Medicines After-Hype Price Prediction Density Analysis
As far as predicting the price of Blueprint Medicines at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Blueprint Medicines or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Blueprint Medicines, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Blueprint Medicines Estimiated After-Hype Price Volatility
In the context of predicting Blueprint Medicines' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Blueprint Medicines' historical news coverage. Blueprint Medicines' after-hype downside and upside margins for the prediction period are 89.67 and 96.51, respectively. We have considered Blueprint Medicines' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Blueprint Medicines is very steady at this time. Analysis and calculation of next after-hype price of Blueprint Medicines Corp is based on 3 months time horizon.
Blueprint Medicines Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Blueprint Medicines is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Blueprint Medicines backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Blueprint Medicines, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.25 | 3.42 | 0.80 | 0.62 | 11 Events / Month | 9 Events / Month | In about 11 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
92.29 | 93.09 | 0.87 |
|
Blueprint Medicines Hype Timeline
Blueprint Medicines Corp is currently traded for 92.29. The entity has historical hype elasticity of 0.8, and average elasticity to hype of competition of -0.62. Blueprint is expected to increase in value after the next headline, with the price projected to jump to 93.09 or above. The average volatility of media hype impact on the company the price is about 106.21%. The price growth on the next news is projected to be 0.87%, whereas the daily expected return is currently at 0.25%. The volatility of related hype on Blueprint Medicines is about 138.88%, with the expected price after the next announcement by competition of 91.67. The company reported the previous year's revenue of 249.38 M. Net Loss for the year was (506.98 M) with profit before overhead, payroll, taxes, and interest of 177.28 M. Given the investment horizon of 90 days the next expected press release will be in about 11 days. Check out Blueprint Medicines Basic Forecasting Models to cross-verify your projections.Blueprint Medicines Related Hype Analysis
Having access to credible news sources related to Blueprint Medicines' direct competition is more important than ever and may enhance your ability to predict Blueprint Medicines' future price movements. Getting to know how Blueprint Medicines' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Blueprint Medicines may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| TERN | Terns Pharmaceuticals | (0.75) | 8 per month | 5.33 | (0.01) | 8.64 | (8.38) | 27.76 | |
| AMLX | Amylyx Pharmaceuticals | 0.04 | 7 per month | 0.00 | (0.15) | 6.96 | (8.30) | 103.39 | |
| ABOS | Acumen Pharmaceuticals | 0.1 | 7 per month | 0.00 | (0.06) | 7.28 | (6.35) | 23.58 | |
| INZY | Inozyme PharmaInc | (0.35) | 8 per month | 4.45 | 0.02 | 8.83 | (8.42) | 25.32 | |
| XFOR | X4 Pharmaceuticals | 0.28 | 8 per month | 4.18 | 0.16 | 10.47 | (7.00) | 37.52 | |
| PTCT | PTC Therapeutics | 1.26 | 9 per month | 0.00 | (0.03) | 4.89 | (5.68) | 19.51 | |
| KRYS | Krystal Biotech | (7.19) | 12 per month | 2.42 | 0.06 | 5.24 | (4.31) | 45.71 | |
| ICPT | Intercept Pharmaceuticals | 0.24 | 7 per month | 1.31 | 0.12 | 4.60 | (3.38) | 83.17 | |
| MDGL | Madrigal Pharmaceuticals | (23.53) | 9 per month | 4.46 | (0.01) | 8.89 | (7.09) | 24.70 | |
| DAWN | Day One Biopharmaceuticals | 0.40 | 9 per month | 3.46 | 0.04 | 5.49 | (5.02) | 20.03 | |
| MREO | Mereo BioPharma Group | (0.02) | 8 per month | 0.00 | (0.03) | 7.69 | (6.07) | 21.23 | |
| ISEE | IVERIC Bio | (0.03) | 10 per month | 0.25 | 0.24 | 2.45 | (1.52) | 18.29 |
Blueprint Medicines Additional Predictive Modules
Most predictive techniques to examine Blueprint price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Blueprint using various technical indicators. When you analyze Blueprint charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Blueprint Medicines Predictive Indicators
The successful prediction of Blueprint Medicines stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Blueprint Medicines Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Blueprint Medicines based on analysis of Blueprint Medicines hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Blueprint Medicines's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Blueprint Medicines's related companies. | 2023 | 2024 (projected) | Dividend Yield | 0.001665 | 9.58E-4 | Price To Sales Ratio | 22.4 | 21.28 |
Story Coverage note for Blueprint Medicines
The number of cover stories for Blueprint Medicines depends on current market conditions and Blueprint Medicines' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Blueprint Medicines is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Blueprint Medicines' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Blueprint Medicines Short Properties
Blueprint Medicines' future price predictability will typically decrease when Blueprint Medicines' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Blueprint Medicines Corp often depends not only on the future outlook of the potential Blueprint Medicines' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Blueprint Medicines' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 60.6 M | |
| Cash And Short Term Investments | 710.6 M |
Check out Blueprint Medicines Basic Forecasting Models to cross-verify your projections. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.